ACP® therapy and SVF® therapy
Injektion von Autologous Conditioned Plasma
ACP® therapy and SVF® therapy
ACP® therapy can have a beneficial effect on:
- Osteoarthritis (wear and tear of the knee, hip, shoulder or other joints)
- Subacromial syndrome
- Acute sports injury of the musculoskeletal system, ligaments and tendons
- Scar pain
- Behandlung chronischer Wunden, auch bei infizierten Wunden wie MRSA
The healing process of an injured or inflamed tissue (e.g. muscle, tendon or cartilage) goes through a complex and precisely regulated series of endogenous processes. Platelets play an important role in this process. At the site of injury, they release growth factors that initiate the reconstruction of the injured tissue and inhibit painful inflammatory processes.
This is the basis of ACP® therapy, whose high concentration of growth factors supports the body's own healing process.
The concentration of all measured growth factors is five to twenty-five times higher in conditioned plasma than in whole blood. ACP® therapy is recommended for painful mild to moderate arthrosis (arthrosis grade I-III). Significant relief can also be achieved in sports injuries of the ligaments and tendons as well as tendonitis, chronic wounds and scar pain.
Generally, three injections are required, each one week apart. A single booster injection every 9 months is often recommended thereafter.
SVF stands for "stromavascular fraction." This is the portion of fat tissue that contains regenerative cells. These cells can be obtained through a special procedure. In addition, the regenerative cells can form into different types of cells such as bone or cartilage. These regenerative cells are found in large quantities in adipose tissue and can be obtained by an appropriate procedure. The regenerative cells of adipose tissue can also release numerous signaling substances that play an important role in tissue regeneration.
The combination of ACP® and SVF®
In recent years, there has been increasing interest in biological treatment options that utilize the properties of platelets and regenerative cells described above. How well ACP® and SVF® work together has already been demonstrated in studies.
For ACP® therapy, a small amount of blood (approx. 15 ml) is taken from your arm vein as for a blood test. This is done using a double-chamber syringe specially developed by the Arthrex® company. This double-chamber system ensures sterile collection and sterile injection of the plasma and thus offers the highest possible safety. By means of a special separation process, the cellular components of the blood (such as the erythrocytes) are separated and the cell-free plasma (PRP=platelet-rich plasma) with the body's own regenerative and, among other things, arthrosis-inhibiting components is obtained.
SVF® stands for "stromavascular fraction". This is the part of adipose tissue that contains regenerative cells. These cells are sterilely extracted under local anesthesia during liposuction (fat suction) of 30ml of fatty tissue from a suitable site (e.g. abdomen, hip or thigh) using a specially designed syringe. SVF® is separated from other substances of the fatty tissue; thus, the body's own regenerative components are obtained
Among other things, the ACP® contains platelets, growth factors, interleukin 7 (anti-inflammatory) and 5-kDa as well as hBD-3 (two antimicrobial peptides). It has long been known that the growth factors contained in the blood can influence various healing processes.
Healing and reconstruction processes take place by injecting the ACP® into the damaged tissue / joint.
If necessary, we combine the two treatment options ACP® and SVF®.
Please ask your attending physician about the costs.
The ACP® therapy as well as the SVF® therapy are not a benefit of the statutory health insurance, not of all health insurances or professional accident insurances. In individual cases, the costs may be covered by the health insurances/insurances. However, these costs are often tax deductible.
For self-payers and privately insured persons, we bill according to the scale of fees for physicians (GOÄ).
Studies on ACP® therapy
Intraartikulare Injektion von thrombozytenangereichertem Plasma zur Behandlung von Knorpelschäden
Orthopädische Praxis 2009
Thanasas C., Papadimitriou G., Charalambidis C., Paraskevopoulos I., Papanikolaou A.
Thrombozytenreiches Plasma versus autologes Vollblut zur Behandlung der chronischen Epicondylitis lateralis des Ellenbogens: eine randomisierte kontrollierte klinische Studie
Amerikanische Zeitschrift für Sportmedizin, Vol. 39, Nr. 10, Seiten 2130-2134, Okt. 2011
Mai-Dan O., Carmont M. R., Laver L., Mann G., Maffulli N., Nyska M.
Plättchenreiches Plasma oder Hyaluronat bei der Behandlung von osteochondralen Läsionen des Talus
Amerikanische Zeitschrift für Sportmedizin, Vol. 40, Nr. 3, Seiten 534-541, März 2012
Studies on SVF® therapy
Loibl M. et al
The effect of leukocyte-reduced platelet-rich plasma on the proliferation of autologous adiposetissue-derived mesenchymal stem cells. Clin Hemorheol Microcirc, 2016;61(4):599614.